Want to see TSE:KNE full AI Analyst Report?
Kane Biotech (KNE) Ratios
Kane Biotech Ratios
TSE:KNE's free cash flow for Q2 2026 was $-634.32K. For the 2026 fiscal year, TSE:KNE's free cash flow was increased by $3.00 and operating cash flow was $-634.32K. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Dec 23 | Mar 23 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.68 | 0.43 | 0.34 | 0.49 | 0.61 |
| Quick Ratio | 0.47 | 0.27 | 0.32 | 0.37 | 0.50 |
| Cash Ratio | 0.36 | 0.15 | 0.07 | 0.17 | 0.24 |
| Solvency Ratio | -0.74 | -0.68 | -0.35 | -0.37 | -0.57 |
| Operating Cash Flow Ratio | -1.30 | -1.71 | -0.30 | -0.48 | -0.48 |
| Short-Term Operating Cash Flow Coverage | -2.61 | -8.90 | -0.46 | -0.73 | -0.96 |
| Net Current Asset Value | $ -1.79M | $ -3.09M | $ -10.37M | $ -6.66M | $ -4.82M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.84 | 0.92 | 1.63 | 1.22 | 0.77 |
| Debt-to-Equity Ratio | -3.09 | -1.41 | -0.88 | -1.05 | -1.21 |
| Debt-to-Capital Ratio | 1.48 | 3.46 | -7.13 | 20.51 | 5.69 |
| Long-Term Debt-to-Capital Ratio | -4.77 | -1.43 | -0.14 | -0.32 | -0.40 |
| Financial Leverage Ratio | -3.66 | -1.53 | -0.54 | -0.86 | -1.58 |
| Debt Service Coverage Ratio | -1.91 | -2.38 | -0.39 | -0.59 | -1.52 |
| Interest Coverage Ratio | -12.82 | -8.24 | -2.76 | -4.23 | -11.74 |
| Debt to Market Cap | 0.29 | 0.10 | 0.74 | 0.53 | 0.19 |
| Interest Debt Per Share | 0.02 | 0.02 | 0.07 | 0.06 | 0.05 |
| Net Debt to EBITDA | -0.48 | -0.52 | -2.63 | -1.95 | -0.84 |
| Profitability Margins | |||||
| Gross Profit Margin | -38.18% | 41.91% | 73.48% | 901.68% | 35.36% |
| EBIT Margin | -727.40% | -188.66% | -2246.83% | -2044.86% | -275.78% |
| EBITDA Margin | -689.37% | -178.17% | -2171.04% | -1880.46% | -264.08% |
| Operating Profit Margin | -727.40% | -215.96% | -2253.58% | -2206.05% | -303.75% |
| Pretax Profit Margin | -661.24% | -214.88% | -3062.39% | -2565.92% | -301.65% |
| Net Profit Margin | -636.00% | -145.35% | -3379.05% | -2481.86% | -286.39% |
| Continuous Operations Profit Margin | -636.00% | -151.91% | -3062.39% | -2565.92% | -301.65% |
| Net Income Per EBT | 96.18% | 67.64% | 110.34% | 96.72% | 94.94% |
| EBT Per EBIT | 90.90% | 99.50% | 135.89% | 116.31% | 99.31% |
| Return on Assets (ROA) | -99.53% | -121.26% | -88.61% | -69.22% | -75.06% |
| Return on Equity (ROE) | 364.51% | 185.64% | 47.68% | 59.64% | 118.49% |
| Return on Capital Employed (ROCE) | -1340.54% | -5336.54% | 64.40% | 479.07% | -345.55% |
| Return on Invested Capital (ROIC) | -192.17% | -478.88% | -179.47% | -97.22% | -124.42% |
| Return on Tangible Assets | -125.65% | -154.46% | -101.75% | -81.15% | -86.79% |
| Earnings Yield | -41.94% | -20.53% | -44.86% | -35.81% | -25.56% |
| Efficiency Ratios | |||||
| Receivables Turnover | 11.72 | 23.62 | 37.86 | 0.27 | 2.70 |
| Payables Turnover | 0.85 | 1.02 | 0.09 | 2.08 | 1.66 |
| Inventory Turnover | 1.17 | 3.21 | 0.16 | 1.64 | 2.00 |
| Fixed Asset Turnover | 0.90 | 2.24 | 0.14 | 0.13 | 1.12 |
| Asset Turnover | 0.16 | 0.83 | 0.03 | 0.03 | 0.26 |
| Working Capital Turnover Ratio | -0.39 | -0.49 | -0.03 | -0.06 | -1.59 |
| Cash Conversion Cycle | -85.15 | -229.16 | -1714.12 | 1402.29 | 97.65 |
| Days of Sales Outstanding | 31.13 | 15.45 | 9.64 | 1355.57 | 135.22 |
| Days of Inventory Outstanding | 311.49 | 113.55 | 2313.39 | 222.02 | 182.35 |
| Days of Payables Outstanding | 427.77 | 358.15 | 4037.15 | 175.30 | 219.92 |
| Operating Cycle | 342.62 | 129.00 | 2323.03 | 1577.59 | 317.56 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.02 | -0.03 | -0.02 | -0.03 | -0.02 |
| Free Cash Flow Per Share | -0.02 | -0.03 | -0.02 | -0.03 | -0.02 |
| Dividend Paid and CapEx Coverage Ratio | -665.46 | -166.16 | -349.61 | -34.76 | -6.47 |
| Capital Expenditure Coverage Ratio | -665.46 | -166.16 | -349.61 | -34.76 | -6.47 |
| Operating Cash Flow Coverage Ratio | -1.41 | -1.79 | -0.35 | -0.44 | -0.49 |
| Operating Cash Flow to Sales Ratio | -7.61 | -1.98 | -21.62 | -19.42 | -1.42 |
| Free Cash Flow Yield | -50.24% | -28.08% | -28.79% | -28.82% | -14.67% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -2.38 | -4.87 | -2.23 | -2.79 | -3.91 |
| Price-to-Sales (P/S) Ratio | 15.17 | 7.08 | 75.32 | 69.31 | 11.21 |
| Price-to-Book (P/B) Ratio | -8.69 | -9.04 | -1.06 | -1.67 | -4.64 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.99 | -3.56 | -3.47 | -3.47 | -6.82 |
| Price-to-Operating Cash Flow Ratio | -1.99 | -3.58 | -3.48 | -3.57 | -7.87 |
| Price-to-Earnings Growth (PEG) Ratio | 0.09 | 0.13 | -0.19 | 0.13 | -0.21 |
| Enterprise Value Multiple | -2.68 | -4.49 | -6.10 | -5.64 | -5.08 |
| Enterprise Value | 7.89M | 16.66M | 19.73M | 16.62M | 21.58M |
| EV to EBITDA | -2.68 | -4.49 | -6.10 | -5.64 | -5.08 |
| EV to Sales | 18.44 | 8.01 | 132.44 | 106.01 | 13.42 |
| EV to Free Cash Flow | -2.42 | -4.03 | -6.11 | -5.31 | -8.16 |
| EV to Operating Cash Flow | -2.42 | -4.05 | -6.12 | -5.46 | -9.43 |
| Tangible Book Value Per Share | -0.01 | -0.02 | -0.07 | -0.04 | -0.02 |
| Shareholders’ Equity Per Share | -0.00 | -0.01 | -0.08 | -0.05 | -0.03 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.04 | 0.29 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.02 | 0.00 | 0.00 | 0.01 |
| Net Income Per Share | -0.02 | -0.02 | -0.04 | -0.03 | -0.04 |
| Tax Burden | 0.96 | 0.68 | 1.10 | 0.97 | 0.95 |
| Interest Burden | 0.91 | 1.14 | 1.36 | 1.25 | 1.09 |
| Research & Development to Revenue | 2.03 | 0.93 | 8.64 | 6.72 | 0.86 |
| SG&A to Revenue | 4.63 | 1.48 | 16.20 | 23.75 | 2.53 |
| Stock-Based Compensation to Revenue | -0.19 | 0.34 | 2.97 | 1.78 | 0.68 |
| Income Quality | 1.20 | 1.30 | 0.64 | 0.80 | 0.47 |
Currency in CAD
